Bristol-Myers lures business thought leader to its research team

US pharma major Bristol-Myers Squibb (NYSE: BMY) has appointed scientific and business thought-leader, Saurabh Saha, senior vice president and global head of translational medicine in the company’s R&D organization, effective today.

“Enhancing our translational medicine capability is critical to achieving our mission, and we are excited to add Dr Saha’s broad leadership experience and deep scientific expertise to our team,” said Dr Tom Lynch, executive VP and chief scientific officer of Bristol-Myers Squibb. “Dr Saha will lead translational research across our therapeutic areas of focus to ensure we have the best understanding of disease and asset-specific biology so we can deliver the right drug to the right patient at the right time.”

Dr Saha said: “Throughout my career, I have had a passion for developing translational research strategies across disease areas, including oncology and immunology. I look forward to working with Tom and the rest of the R&D organization to advance Bristol-Myers Squibb’s industry-leading pipeline in a way that pushes the boundaries of science and enables us to rapidly deliver innovative medicines to patients with even greater precision.”